Fatty acid amide hydrolase inhibition for treatment of amyotrophic lateral sclerosis.
Overview
- Department of Neurology
- Department of Clinical Research Education
- Department of Pathophysiological Laboratory Sciences
- Division of Systems Biology
- Public Health Informatics Unit, Department of Integrated Health Sciences, and
- Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
- Institute for Advanced Research, Nagoya University, Nagoya, Aichi, Japan
- Department of Biochemistry, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
- Department of Neural iPSC Research Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Aichi, Japan
- Department of Neurology and
- Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
- Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan
Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease caused by the selective loss of upper and lower motor neurons. There is a considerable variability in the disease progression of sporadic ALS, but the molecular basis for phenotypic heterogeneity remains largely unknown. Patients with ALS often manifest systemic metabolic abnormalities such as glucose intolerance and hypermetabolic state. We conducted reverse translational research to explore therapeutic targets in ALS based on the systemic metabolic alterations in patients and identified several metabolites associated with the disease progression, including metabolites involved in the expanded endocannabinoid system (ECS). In particular, the levels of N-acyl taurines (NATs) were correlated with the longitudinal change in the revised ALS functional rating scale and survival. Experiments with ALS cellular models and induced pluripotent stem (iPS) cells derived from patients with ALS and SOD1G93A transgenic mice revealed that PF-04457845, a fatty acid amide hydrolase inhibitor, upregulated the expanded ECS, particularly the levels of NATs and ameliorated motor neuron degeneration through the regulation of microglial environment, synapse plasticity, and neuronal development. These results collectively indicate that dysregulation of NATs is associated with ALS progression and PF-04457845 may represent a potential disease-modifying therapy for ALS.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- doi:10.17632/
f8gtkwfs6s.1 , at the source; found in “Data availability” - geo:GSE242942, at NCBI GEO; found in “Data availability”
Data availability
The metabolomics source data were deposited into Mendeley (doi:10.17632/
Values for all data points in graphs are reported in the Supporting Data Values file.
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 2, 28 September 2026
- Authors: added Teppei Shimamura (0000-0003-2994-872X); Yohei Okada (0000-0001-5253-8556); Takehiko Yokomizo (0000-0002-5219-1553); removed Teppei Shimamura; Yohei Okada; Takehiko Yokomizo
- Funding: added Japan Agency for Medical Research and Development: JP24wm0625301, 22nk0101575h0002, JP21wm0425008, JP22am0401007, JP21wm0425008,JP21wm0425013,JP22nk0101575,JP22am0401007,JP23bm1423006,JP24wm0625301, JP21wm0425013; Mitsubishi Tanabe Pharma Corporation; Japan Society for the Promotion of Science: JP22am0401007, 20H00527, 21K15677, 23H00420, 23K14773, JP22nk0101575
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 23 authors, 5 keywords, 15 MeSH terms, 75 references.
Cite
This paper
Ito, D., Iida, M., Iguchi, Y., Hashizume, A., Yamada, S., Kishimoto, Y., Komori, S., Obara, K., Nishisaki, S., Yokoi, S., Shimamura, T., Takemoto, Y., Nakatochi, M., Akashi, T., Hinohara, K., Lee-Okada, H.-C., Okada, Y., Niwa, J., Sobue, G., . . . Katsuno, M. (2026). Fatty acid amide hydrolase inhibition for treatment of amyotrophic lateral sclerosis. JCI insight, 11(15), e198842. https://
BibTeX
@article{ito2026fatty,
author = {Ito, Daisuke and Iida, Madoka and Iguchi, Yohei and Hashizume, Atsushi and Yamada, Shinichiro and Kishimoto, Yoshiyuki and Komori, Shota and Obara, Kazuki and Nishisaki, Shuto and Yokoi, Satoshi and Shimamura, Teppei and Takemoto, Yuto and Nakatochi, Masahiro and Akashi, Tomohiro and Hinohara, Kunihiko and Lee-Okada, Hyeon-Cheol and Okada, Yohei and Niwa, Junichi and Sobue, Gen and Tanaka, Shinji and Takashina, Ken and Yokomizo, Takehiko and Katsuno, Masahisa},
title = {{Fatty acid amide hydrolase inhibition for treatment of amyotrophic lateral sclerosis}},
journal = {JCI insight},
year = {2026},
month = jun,
volume = {11},
number = {15},
pages = {e198842},
publisher = {American Society for Clinical Investigation},
issn = {2379-3708},
doi = {10.1172/
url = {https://
pmid = {42275159},
pmcid = {PMC13463617}
}
RIS
TY - JOUR
AU - Ito, Daisuke
AU - Iida, Madoka
AU - Iguchi, Yohei
AU - Hashizume, Atsushi
AU - Yamada, Shinichiro
AU - Kishimoto, Yoshiyuki
AU - Komori, Shota
AU - Obara, Kazuki
AU - Nishisaki, Shuto
AU - Yokoi, Satoshi
AU - Shimamura, Teppei
AU - Takemoto, Yuto
AU - Nakatochi, Masahiro
AU - Akashi, Tomohiro
AU - Hinohara, Kunihiko
AU - Lee-Okada, Hyeon-Cheol
AU - Okada, Yohei
AU - Niwa, Junichi
AU - Sobue, Gen
AU - Tanaka, Shinji
AU - Takashina, Ken
AU - Yokomizo, Takehiko
AU - Katsuno, Masahisa
TI - Fatty acid amide hydrolase inhibition for treatment of amyotrophic lateral sclerosis
T2 - JCI insight
J2 - JCI Insight
PY - 2026
DA - 2026/
VL - 11
IS - 15
SP - e198842
SN - 2379-3708
PB - American Society for Clinical Investigation
DO - 10.1172/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1172/
"type": "article-journal",
"title": "Fatty acid amide hydrolase inhibition for treatment of amyotrophic lateral sclerosis",
"container-title": "JCI insight",
"author": [
{
"family": "Ito",
"given": "Daisuke"
},
{
"family": "Iida",
"given": "Madoka"
},
{
"family": "Iguchi",
"given": "Yohei"
},
{
"family": "Hashizume",
"given": "Atsushi"
},
{
"family": "Yamada",
"given": "Shinichiro"
},
{
"family": "Kishimoto",
"given": "Yoshiyuki"
},
{
"family": "Komori",
"given": "Shota"
},
{
"family": "Obara",
"given": "Kazuki"
},
{
"family": "Nishisaki",
"given": "Shuto"
},
{
"family": "Yokoi",
"given": "Satoshi"
},
{
"family": "Shimamura",
"given": "Teppei"
},
{
"family": "Takemoto",
"given": "Yuto"
},
{
"family": "Nakatochi",
"given": "Masahiro"
},
{
"family": "Akashi",
"given": "Tomohiro"
},
{
"family": "Hinohara",
"given": "Kunihiko"
},
{
"family": "Lee-Okada",
"given": "Hyeon-Cheol"
},
{
"family": "Okada",
"given": "Yohei"
},
{
"family": "Niwa",
"given": "Junichi"
},
{
"family": "Sobue",
"given": "Gen"
},
{
"family": "Tanaka",
"given": "Shinji"
},
{
"family": "Takashina",
"given": "Ken"
},
{
"family": "Yokomizo",
"given": "Takehiko"
},
{
"family": "Katsuno",
"given": "Masahisa"
}
],
"container-title-short":
"volume": "11",
"issue": "15",
"page": "e198842",
"DOI": "10.1172/
"PMID": "42275159",
"PMCID": "PMC13463617",
"ISSN": "2379-3708",
"publisher": "American Society for Clinical Investigation",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
6,
11
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1038/s41573-022-00612-2
- Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation.Journal: Nature reviews. Drug discoveryIn common: other condition, 11 references
- [2] doi:10.1073/pnas.2513642123
- Neuronal TDP-43 regulates myelin formation via neurexin 1 mRNA stabilization.Journal: Proceedings of the National Academy of Sciences of the United States of AmericaIn common: other condition, mouse, 5 references, author Yohei Okada
- [3] doi:10.1186/s13024-022-00593-1
- Advances in sequencing technologies for amyotrophic lateral sclerosis research.Journal: Molecular neurodegenerationIn common: other condition, 8 references
- [4] doi:10.1038/s41467-026-70244-2 [code]
- Restoring early postnatal synaptic dysregulation rescues motor neuron degeneration in a mouse model of Spinal and Bulbar Muscular Atrophy.Journal: Nature communicationsIn common: other condition, mouse, 3 references, author Yohei Okada
- [5] doi:10.1038/s41467-025-59679-1 [code]
- Single-cell RNA-sequencing reveals early mitochondrial dysfunction unique to motor neurons shared across FUS- and TARDBP-ALS.Journal: Nature communicationsIn common: other condition, 7 references
- [6] doi:10.1038/s41593-025-02118-7 [code]
- Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy.Journal: Nature neuroscienceIn common: other condition, 6 references
- [7] doi:10.1038/s42003-025-09168-4 [code]
- A genome-wide association study identifies the GPM6A locus associated with age at onset in ALS.Journal: Communications biologyIn common: other condition, 2 references, author Yohei Okada
- [8] doi:10.1186/s40478-022-01376-x
- The distribution and function of GDE2, a regulator of spinal motor neuron survival, are disrupted in Amyotrophic Lateral Sclerosis.Journal: Acta neuropathologica communicationsIn common: other condition, mouse, 5 references
- [9] doi:10.1038/s42003-022-03128-y
- Neuronal-glial communication perturbations in murine SOD1<sup>G93A</
sup> spinal cord. Journal: Communications biologyIn common: other condition, mouse, 5 references - [10] doi:10.1016/j.ymthe.2025.05.010
- RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice.Journal: Molecular therapy : the journal of the American Society of Gene TherapyIn common: other condition, mouse, 5 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
